4:41 PM
 | 
Sep 12, 2018
 |  BC Extra  |  Politics & Policy

China biopharma stocks fall after centralized tendering talks

Stocks of Chinese biopharma companies slid on Wednesday, possibly in response to a meeting Tuesday of China's National Medical Insurance Bureau on the centralized procurement of generics. Under centralized procurement, a single generic manufacturer would gain a 70% market share in 11 Chinese cities, according...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >